Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2009
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. Key metrics related to the transaction include:
- Gross Proceeds Raised: $1,251,000
- Common Stock Issued: 1,345,161 shares
- Price Per Share: $0.93
- Warrants Issued: 672,581 (representing 50% of shares purchased)
- Warrant Exercise Price: $1.12
- Warrant Expiration: July 24, 2014
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of 1,345,161 new shares and associated warrants to eight accredited investors. The securities were sold under Section 4(2) and Regulation D exemptions.
Guidance, Outlook, and Restrictions
- Lock-Up Period: Investors agreed not to sell, pledge, short, or dispose of the purchased shares or warrants from the purchase date until January 31, 2010.
- Exhibits: The press release dated July 30, 2009, and forms of subscription agreements/warrants are filed as exhibits to the Form 10-Q for the quarter ended June 30, 2009.
- Management Commentary: No specific outlook or management commentary regarding future operations is included in this text.
Investor Verification Checklist
- Verify the impact of the 1,345,161 new shares on total outstanding share count and earnings per share.
- Review the Form 10-Q for the quarter ended June 30, 2009, for the full subscription agreements and warrant terms.
- Confirm the company's cash position post-transaction to assess runway for operations.
- Monitor compliance with the lock-up agreement expiring January 31, 2010.